Do analysts expect SAGE Therapeutics Inc (SAGE) stock to rise after falling -18.39% in one month?
Analysts who follow SAGE Therapeutics Inc (SAGE) on average expect it to gain 89.03% over the next twelve months. These same analysts give the stock an average Buy rating. This average rating gives SAGE an analyst rank of 29, meaning it ranks higher than 29 stocks, based on data compiled by Investors Observer.
Why are analyst ratings important?
You can learn a lot about a business by looking at its financial statements and comparing them to other businesses. Analysts who cover an industry in depth, however, can add even more to your research. They usually follow a particular sector or industry very closely. They also pay attention and ask questions on income conference calls and other events where they might learn information that shows up in the numbers.
Investors Observer takes the average score of these analysts, then the percentile ranks these averages. This allows you to compare stocks much more accurately than just seeing the typical five-level rating system used on most Wall Street.
What is happening with the shares of SAGE Therapeutics Inc today?
SAGE Therapeutics Inc (SAGE) stock is up 6.7% while the S&P 500 fell -0.13% at 11:37 a.m. on Monday August 9. SAGE was up $ 2.76 from the previous closing price of $ 41.09 on volume of 372,251 shares. Over the past year, the S&P 500 has risen 31.85% while the SAGE has fallen -17.75%. SAGE has earned $ 11.84 per share over the past 12 months, giving it a price / earnings ratio of 3.7. Click here for the full report on SAGE Therapeutics Inc.